论文部分内容阅读
肺癌是临床最常见的恶性肿瘤,已成为发达地区恶性肿瘤死亡的首要原因。初诊的肺癌中的75%-80%[1],患者就诊时因分期晚失去手术机会,非小细胞肺癌(NSCLC)约占全部肺癌的80%,化疗成为其主要的治疗方法。多西紫杉醇无论单药或联合一线治疗NSCLC有效率高及毒副反应轻,我院于2009年1月-2011年2月,用多西紫杉醇联合卡铂治疗43例晚期NSCLC,现报告如下:1资料与方法
Lung cancer is the most common malignant tumor in clinic and has become the leading cause of death of malignant tumor in developed areas. 75% -80% of newly diagnosed lung cancer [1], patients lost their chance of surgery due to staging late, and non-small cell lung cancer (NSCLC) accounts for about 80% of all lung cancer. Chemotherapy has become the main treatment. Docetaxel either single-drug or combination of first-line treatment of NSCLC efficient and toxic side effects, our hospital in January 2009 -2011 in February, with docetaxel combined carboplatin in 43 cases of advanced NSCLC are reported as follows: 1 data and methods